Helsinn Birex Pharmaceuticals Ltd., Dublin (HBP)

In 2009, the Helsinn Group invested in a new Centre-of-Excellence for oral solid dosage forms and a stability center to support the development of a group of new solid dose products. In 2014, the first new product from this facility was approved by the FDA and launched on the US market. To date, in the region of CHF60million has been invested in the Dublin site, as well as the sites of its strategic contract-manufacturing partners, which provide more dedicated capacity. Together, these investments guarantee reliability of all elements of the supply chain both for development and commercial products.